Welcome to the e-CCO Library!

P033: Single-cell analysis of gut mucosal- and peripheral blood cells in ulcerative colitis patients undergoing vedolizumab treatment
Year: 2022
Source: ECCO'22
Authors: Karmi, N.(1);Sun, S.(1);de Jong, S.(1);Bangma, A.(1);Teunis, J.(2);Paraskevopoulou, M.(3);Juarez, J.(3);Bleck, B.(3);Farahmand, S.(3);Weersma, R.(1);Bigaeva, E.(1);Festen, E.(1);
Created: Friday, 11 February 2022, 3:52 PM
P033: The assessment of serum cytokines at baseline could predict mucosal healing in patients with Crohn's disease treated with ustekinumab. A prospective study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BertaniMD, L.(1)*;Antonioli, L.(2);Fornili, M.(2);D'Antongiovanni, V.(2);Coppini, F.(1);Ceccarelli, L.(3);Carmisciano, L.(2);Benvenuti, L.(2);Mumolo, M.G.(3);Bottari, A.(1);Baglietto, L.(2);Bellini, M.(1);Fornai, M.(2);De Bortoli, N.(1);Costa, F.(3);
Created: Friday, 14 July 2023, 10:48 AM
P033: The efficacy of tonsil-derived mesenchymal stem cells conditioned medium in chronic colitis model
Year: 2018
Source: ECCO '18 Vienna
Authors:

A.R. Choe*, S.-A. Jung, Y.-H. Joo, C.H. Tae, S.Y. Han, H.K. Jeon, J.W. Kim, S.H. Park, C.M. Moon, S.-E. Kim, K.-N. Shim, H.-K. Jung

Created: Thursday, 21 February 2019, 9:14 AM
P034 GB004, a novel gut-targeted prolyl hydroxylase inhibitor, induces HIF-1α target genes and is efficacious in mouse colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Taylor Meadows1, M. Kennedy2, Z. Naiman1, M. Sergeeva2, B. Paulson2, G. Opiteck3, D. Slee4, L. Carter1, L. Salter-Cid4

Created: Thursday, 30 January 2020, 10:12 AM
P034: A common IL2RA polymorphism alters natural killer cell immunophenotype and function in Crohn's disease, with implications for IL-2 based therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Clough, J.(1)*;Roberts, L.(2);Goldberg, R.(2);Lord, G.(3);Irving, P.(1);
Created: Friday, 14 July 2023, 10:48 AM
P034: A dietary fibre intervention shapes the microbiome towards an anti-inflammatory tone
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. J. Reider*1,2, S. Moosmang3, J. Tragust1, L. Trgovec-Greif4, S. Tragust5, N. Przysiecki1, S. Sturm3, H. Tilg2, T. Rattei4, H. Stuppner3, A. R. Moschen1,2

Created: Friday, 22 February 2019, 9:41 AM
P034: Altered microbiota and host-bacterial interactions during the spontaneous development of colitis in IL-10 knockout mice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lόpez-Estévez S., Aguilera M., Martínez V.

Created: Wednesday, 20 February 2019, 10:36 AM
P034: DISRUPTive liquid biopsies in Inflammatory Bowel Disease (DISRUPT-IBD): Release of exosomal and molecular tissue signals by transabdominal ultrasound?
Year: 2022
Source: ECCO'22
Authors: Tran, F.(1,2);Scharmacher, A.(1);Mishra, N.(1);Barann, N.(1);Sievers, L.K.(1,2);Juzenas, S.(1);Bernardes, J.P.(1);Lessing, M.(2);Lassen, A.(2);Rosenstiel, P.(1);Schreiber, S.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P034: Human primary 2D culture as a tool to explore JAK1 pathway inhibition in the intestinal epithelium using siRNA technology
Year: 2021
Source: ECCO'21 Virtual
Authors: Dotti, I.(1);Sulpice, E.(2);Nougarède, A.(3);Jary, D.(3);Clément, F.(2);Gidrol, X.(2);Navarro, F.(3);Salas, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P034: Immunoregulatory properties of human adipose–derived stem cells in inflammatory diseases: differences between Crohn´s disease and obesity
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Serena*1, 2, N. Keiran2, M. Millan2, M. Ejarque1, 2, R. Fradera3, E. Espin4, K. Roche1, 2, J. Vendrell1, 2, S. Fernandez-Veledo1, 2

Created: Friday, 22 February 2019, 9:49 AM
P034: Validation of a novel xenograft mouse model for intestinal fistulas
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.S. Bruckner1,2*, N. Marsiano3, E. Nissim-Eliraz3, E. Nir3, M. Leutenegger1, C. Gottier1, S. Lang1,2, M. Spalinger1,2, G. Rogler1,4, S. Yagel5, SysmedIBD EU research consortium, N.Y. Shpigel 3*

Created: Thursday, 21 February 2019, 9:14 AM
P035 NUDT15 variance increases DNA-incorporated thiopurine metabolites and lymphocyte apoptosis in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H. Kiyohara1, T. Toyonaga1, S. Kuronuma2, A. Ueno3, S. Okabayashi3, R. Ozaki1, O. Takeuchi2, S.A. Coulthard4, C.P.F. Redfern4, H. Terai5, Y. Tanaka6, M. Nakano1, T. Hibi3, T. Kobayashi3

Created: Thursday, 30 January 2020, 10:12 AM
P035: An examination of resting state functional connectivity in patients with active Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Thapaliya, G.(1);Eldeghaidy, S.(2);Radford, S.(3);Francis, S.(2);Moran, G.(3);
Created: Friday, 11 February 2022, 3:52 PM
P035: Anti-inflammatory Effect and Mechanism of Action of BMC333, a Rationally-Designed Live Bacterial Consortium Based on Microbiome Functional Genomic Analysis for Treating IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tirosh, O.(1);Meshner, S.(1);Eshar, S.(1);Kruger Ben-Shabat, S.(1);Polonski, O.(1);Haber, E.(1);Liu, B.(2);Herzog, J.(2);Sartor, R.B.(2);Ringel, Y.(3)*;
Created: Friday, 14 July 2023, 10:48 AM
P035: Lamina propria CD4+LAP+ Foxp3- regulatory cells are involved in limiting the disease extension in Ulcerative Colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Butera1, A. Amendola1, M. Sanchez2, S. Piroli3, A. Pronio3, D. De Nitto4, R. Pica4, M. Boirivant*1

Created: Friday, 22 February 2019, 9:49 AM
P035: Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Lewis*1, A. Nijhuis1, G. Berti1, C. L. Bishop2, R. Feakins3, J. O. Lindsay4, A. Silver1

Created: Friday, 22 February 2019, 9:41 AM
P035: Potential biomarkers for diagnosis through proteomics, in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Muñoz-Villafranca, C.(1);Aresti Goiriena, U.(2);Ispizua, N.(1);Irigoyen Muñoz, M.(3);Rivera Garcia, N.A.(2);Ortiz de Zárate, J.(1);Arreba Gonzalez , P.(1);Calderón García, Á.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P035: Serum markers predict outcome to ustekinumab in patients with refractory Crohn’s disease and provide insides in the mechanism of action
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, S. Vermeire1,2, S. Verstockt3, B. Creyns4, N. Ardeshir Davani2, C. Breynaert4, G. Van Assche1,2, G. Van Assche1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
P035: TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Verstockt B.*1,2, Arijs I.1,3,4, de Bruyn M.1,5, Verstockt S.6, Van Assche G.1,7, Breynaert C.8, Vermeire S.1,7, Ferrante M.1,7

Created: Wednesday, 20 February 2019, 10:36 AM
P036 A novel p53-mediated mouse model of inflammatory bowel disease-associated colorectal cancer
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.M. Churchhouse1, C.V. Billard1, M.J. Arends2, K.B. Myant1

Created: Thursday, 30 January 2020, 10:12 AM